KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q3 2025 value amounting to $1.2 billion.

  • Teva Pharmaceutical Industries' Shares Outstanding (Diluted Average) rose 273.61% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 273.61%. This contributed to the annual value of $1.1 billion for FY2024, which is 107.24% up from last year.
  • Teva Pharmaceutical Industries' Shares Outstanding (Diluted Average) amounted to $1.2 billion in Q3 2025, which was up 273.61% from $1.2 billion recorded in Q2 2025.
  • Teva Pharmaceutical Industries' 5-year Shares Outstanding (Diluted Average) high stood at $1.2 billion for Q3 2025, and its period low was $1.1 billion during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $1.1 billion (2022), whereas its average is $1.1 billion.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Shares Outstanding (Diluted Average) decreased by 17.62% in 2024 and then surged by 320.57% in 2025.
  • Teva Pharmaceutical Industries' Shares Outstanding (Diluted Average) (Quarter) stood at $1.1 billion in 2021, then increased by 0.27% to $1.1 billion in 2022, then increased by 0.81% to $1.1 billion in 2023, then rose by 1.07% to $1.1 billion in 2024, then increased by 2.92% to $1.2 billion in 2025.
  • Its Shares Outstanding (Diluted Average) was $1.2 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.2 billion in Q1 2025.